Monoclonal antibody: a cell specific immunotherapy to treat cancer
No Thumbnail Available
Date
2023-04
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Fundamentally, the therapy technique which is utilized in malignancy immunotherapy, monoclonal antibodies (mAb), is one of them, and it is used extensively as a treatment for the disease. To achieve more successful treatment, novel combination treatments and treatment procedures must be created. The purpose of this study is the improvement of mAb treatment and detail late advance and new limits, particularly in cancer therapy. With various keywords, we searched Google Scholar, PubMed, and Scopus for monoclonal antibody therapy as an alternate form of chemotherapy. The number of patients who received each therapy regimen, and the recovery rate are all displayed in this study, also a comparative study between monotherapy and chemotherapy. The result showed that rituximab had a greater overall response rate than other drugs, at 68%. In the combination treatment group (monotherapy+chemotherapy), 100% of patients had adverse events, compared to 84.2 percent in the monotherapy group. The pharmaceutical industry's fastest-growing medications, monoclonal antibodies are increasingly being examined in Clinical trials as stand-alone treatments or in conjunction with other therapies. It has a promising future since it will provide better tailored therapy and combination therapy for the treatment of cancer.
Description
Keywords
Monoclonal antibody, Combined chemotherapy, Antibody-drug conjugates, Immunotherapy, Cancer
Citation
Rahman M. A., Islam F., Hasan M., Joya I. S., Mithila M. M., Islam M. F., Rahman M. R.. Monoclonal antibody: a cell specific immunotherapy to treat cancer. International Journal of Basic & Clinical Pharmacology. 2023 Mar; 12(2): 290-302